Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie - Johnson & Johnson (NYSE:JNJ), Protagonist Therapeutics (NASDAQ:PTGX)
Published on March 19, 2026.
Johnson & Johnson (JNJ), Protagonist Therapeutics (NASDAQ:PTGX) have won the FDA approval for Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older. The approval could increase competition with AbbVie's Skyrizi (ISR-rzaa), which is predicted to grow by 23% in fiscal 2026. The FDA approval of Icotryde triggers a $50 million milestone payment to Protagonist, and it is eligible to receive up to $580 million in potential additional regulatory and sales milestone payments.
Related Articles
Covid inquiry NHS report key findings - from impact of Stay at home advice to visiting rules
The report from the Coventry inquiry reveals significant flaws in the system, particularly regarding patient delays, and the potential for future conflicts like that of Brexit.
Robinhood Trends As Social Feature, Platinum Card Launch Drive Buzz - Robinhood Markets (NASDAQ:HOOD)
Robinhood Markets, Inc. is trending on social media as Robinhood Social and Platinum Card launches, with weaker stock and weaker momentum compared to broader market trends.
Dow Falls Over 300 Points; US Initial Jobless Claims Fall - China Natural Resources (NASDAQ:CHNR), Reviva Pharmaceuticals (NASDAQ:RVPH)
The Dow Jones index fell over 300 points, while European markets also fell, driven by falling commodity prices and unexpected jobless claims.